Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ML-PRIM
- Development stage
- Unknown
- Lead developer
- Gelpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ML-PRIM** is an oral fixed-dose soft-gelatin-capsule combination of methocarbamol 375 mg and ibuprofen 200 mg developed and manufactured by Gelpharma. It combines the centrally acting skeletal-muscle-relaxant effects of methocarbamol with the analgesic and anti-inflammatory effects of the nonsteroidal anti-inflammatory drug ibuprofen for relief of musculoskeletal pain associated with muscle contractures, spasms, inflammation, and reduced mobility. ([gelpharma.com](https://gelpharma.com/productos/ml-prim/))
- Brand names
- ML-PRIM
- Other names
- ibuprofen + methocarbamol
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on ML-PRIM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ML-PRIM.